Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence

Anticancer Research

Volumn 32, Issue 1, 2012, Pages 105-114

  Yamade, Mihoko ^a   Sugimoto, Mitsushige ^a   Nishino, Masafumi ^a   Uotani, Takahiro ^a   Sahara, Shu ^a   Iwaizumi, Moriya ^a   Yamada, Takanori ^a   Osawa, Satoshi ^a   Sugimoto, Ken ^a   Miyajima, Hiroaki ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

H2AX; DNA double strand breaks; Gastric cancer; HER2; SN 38; Trastuzumab

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H2AX; TRASTUZUMAB;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DRUG ADMINISTRATION SCHEDULE; FLOW CYTOMETRY; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84855649906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Albarello L, Pecciarini L, and Doglioni C: HER2 testing in gastric cancer. Adv Anat Pathol 18: 53-59, 2011.
2. Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
3. Baselga J and Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12(Supp 1): S35-41, 2001. (Pubitemid 32750583)
4. Mukai H: Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol 15: 335-340, 2010.
5. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, and Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 27: 681-685, 2005.
6. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo, Elenius K and Isola J: Amplification of HER2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005. (Pubitemid 40309309)
7. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K and Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59: 795-805, 2007. (Pubitemid 46440603)
8. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Uhle M, Ruschoff J and Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
9. Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J and Dikomey E: The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 9: 889-897, 2010.
10. Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E and Kriegs M: In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-RAS status. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 101: 147-151, 2011.
11. Okines AF and Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer 46: 1949-1959, 2010.
12. Pommier Y: Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802, 2006.
13. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, Nussenzweig A, Aladjem MI, Bonner WM and Pommier Y: Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278: 20303-20312, 2003. (Pubitemid 36799229)
14. Cliby WA, Lewis KA, Lilly KK and Kaufmann SH: S-Phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277: 1599-1606, 2002. (Pubitemid 34968919)